FDA

Key Takeaways FDA critically addressed misleading claims about a cancer treatment. ImmunityBio’s Anktiva was inaccurately marketed as effective for all cancers. Important details were omitted from advertisements, including necessary combination treatments and risks. The FDA highlighted unsupported claims of patients being “cancer free” from the treatment. Article Patrick Soon-Shiong, a notable but often controversial figure …

Key Takeaways: The FDA’s food policy strategy for 2026 prioritizes infant formula safety, updated food labels, and identifying ultra-processed foods. There will be an increased focus on inspections of food processing plants and enhancing seafood safety programs. The shift in focus from vaccines to food issues aligns with growing public interest and upcoming midterm elections. …

Key Takeaways Insight from a Biotech Leader: Stelios Papadopolous shares valuable perspectives at a major biotech summit. Weight Loss Breakthroughs: New data from Structure Therapeutics and Eli Lilly are creating buzz in the industry. FDA Changes: Recent staffing movements at the FDA could impact drug development. New Treatments: Johnson & Johnson announces a breakthrough drug …

Understanding the Critique of Biotech and Pharma: A Balanced View Key Takeaways: Criticism in the biotech industry often comes from opposing viewpoints. Accusations can swing dramatically between supporting and undermining the industry. It’s essential to separate facts from biases when discussing drug development and companies. In the fast-paced world of biotech and pharmaceuticals, opinions can …

Making Medical Innovations Accessible: Why Breakthrough Technologies Matter Medical technologies have the potential to transform lives, but their impact is only felt when they are accessible to those who need them. As both a physician and inventor, I see how vital it is for healthcare providers to have a range of effective treatment options at …

Key Takeaways A new biotech investment firm has raised $100 million with ties to Jeffrey Epstein. Vinay Prasad’s potential return to the FDA is under discussion. The latest episode of “The Readout LOUD” dives into various biotech developments, including drug approvals and partnerships. Have you ever wondered how connections can shape the world of biotech …

Key Takeaways The Trump administration criticized an experimental treatment for Huntington’s disease through a private press conference. Typically, the FDA holds public meetings for transparent discussions on controversial issues. UniQure’s proposed treatment showed promise in trials, but the FDA remains skeptical. Understanding FDA’s Role in Drug Approvals Navigating the world of drug approvals can feel …

Vinay Prasad’s Departure from the FDA: What You Need to Know In a significant shakeup, Vinay Prasad, a prominent official at the Food and Drug Administration (FDA), is set to leave the agency for the second time at the end of April. Prasad’s tenure has been filled with controversy, particularly within the Center for Biological …

Key Takeaways: Prime Medicine is seeking FDA approval for a novel gene-editing treatment. The treatment utilizes prime editing, a CRISPR-based tool introduced in 2019. It aims to help patients with chronic granulomatous disease (CGD) by correcting DNA defects. The FDA’s response to this application will be closely monitored amid growing scrutiny on gene therapies. This …

Building Bridges for Kids with Rare Diseases: A New Hope Every parent pictures a bright, healthy future for their child. For me, that dream felt shattered when my son Wheeler was just four weeks old. He was diagnosed with CLN3 juvenile Batten disease, a rare genetic condition that progressively robs children of their vision, memory, …